

This document is a translation of the original German version and is intended to be used for informational purposes only. While every effort has been made to ensure the accuracy and completeness of the translation, please note that the German original is binding.

Annual General Meeting
**Münchener Rückversicherungs-Gesellschaft
Aktiengesellschaft in München**

at 10 a.m. (CEST) on Wednesday, 28 April 2021,
to be held as a **Virtual Annual General Meeting**

Additional information about agenda item 5 (Resolution to elect a member of the Supervisory Board)

The Supervisory Board has nominated the proposed candidate for election based on pre-determined, objective criteria. The task of selecting the candidate and preparing the nomination was assigned to the Supervisory Board's Nomination Committee, pursuant to the Rules of Procedure for the Supervisory Board.

The Nomination Committee drafted a requirements profile for selecting the candidate. In considering the nomination, the Nomination Committee was guided by the objectives determined by the Supervisory Board regarding its composition, the competence profile for the overall Supervisory Board, and the set of criteria for the shareholder representatives, among others. A key criterion in selecting the candidate was to ensure availability on the Supervisory Board of the requisite knowledge, expertise and experience important for the task of advising on and monitoring the Company's business activities as a whole.

In addition, the Nomination Committee set high standards as to the candidate's character. Key aspects here include a commitment to a long-term, sustained increase in value. A further important criterion in the selection process is the personal independence of the candidate, given that the members of the Supervisory Board represent the interests of all shareholders. The Supervisory Board considers the proposed candidate to be independent within the meaning of the GCGC.

In selecting the candidate, due regard was paid to diversity on the Supervisory Board.

Further information about the candidate can be found on the following pages. This information is also available and regularly updated on our internet site at www.munichre.com/supervisory-board



Dr. Carinne Knoche-Brouillon
Laubenheim, Germany

Member of management
C.H. Boehringer Sohn AG & Co. KG, Ingelheim

Personal data

Date of birth: 5 June 1965
Place of birth: Karlsruhe, Germany
Nationalities: French, German

Education:

1994 Management course
(Ecole Supérieure de Commerce de Lyon, France)
1989 to 1990 Master's in Marketing Management
(Institut de Pharmacie Industrielle de Lyon,
France)
1983 to 1990 Doctoral studies in pharmacology (Faculté de
Pharmacie de Lyon, France)

Professional career

since January 2020 Member of management
C.H. Boehringer Sohn AG & Co. KG, Ingelheim
2018 to 2019 Global Head of Therapeutic Areas, Boehringer
Ingelheim International GmbH, Ingelheim
2014 to 2018 Head of Global Commercial Strategy ZNS, Janssen
Global Services LLC (Johnson & Johnson's
Pharmaceutical Company), Raritan, USA
2012 to 2014 President, Janssen Therapeutics Inc., Titusville,
USA
Member of Janssen North America Leadership
Team
1997 to 2012 Various positions within Johnson & Johnson Inc.,
New Brunswick, USA, marketing and sales and
Head of EMEA (Europa, Middle East, Africa)
1996 to 1997 Business Development Manager, FDM Pharma
SRL, Paris, France
1991 to 1995 Management positions at Biomérieux SA, Lyon,
France, most recently marketing manager for
microbiology

Memberships of other statutory supervisory boards

None

Membership of comparable bodies of German and foreign business enterprises

None

Other important activities

None

Relevant knowledge, expertise and professional experience

Based on her many years of experience and broad management expertise, Dr. Knoche-Brouillon possesses comprehensive knowledge of strategic and operational business management. Thanks to her position as a member of management at one of the world's most important family businesses in its field, she will also bring experience from a different governance environment to her Supervisory Board work. She will also enrich the Supervisory Board with her scientific expertise, her internationality and her knowledge of personnel management.

In the Supervisory Board's assessment, Dr. Knoche-Brouillon does not have any personal or business relations with Munich Reinsurance Company, its Group companies, the governing bodies of Munich Reinsurance Company, or with a shareholder holding a material interest in Munich Reinsurance Company, which would require disclosure under recommendation C.13 of the GCGC. Moreover, the Supervisory Board has satisfied itself that Dr. Knoche-Brouillon can devote the expected amount of time required for this office.